Reports
As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.
Global Malignant Mesothelioma Therapeutics Market: By Application: Hospital Pharmacies, Retail Pharmacies, Oncology Centers, Others; By Product: Chemotherapy, Other Therapeutics; Regional Analysis; Historical Market and Forecast (2016-2026); Market Dynamics; SWOT Analysis; Competitive Landscape; Industry Events and Developments
Global Malignant Mesothelioma Therapeutics Market Outlook
The global malignant mesothelioma therapeutics market is projected to grow at a CAGR of 7.4% in the forecast period of 2021-2026.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The rising awareness regarding the treatment of mesothelioma and the availability of advanced therapeutics procedures is expected to aid the industry over the forecast period. Further, the use of asbestos in various products and sectors, which is a major cause for the development of mesothelioma, is expected to drive the global market for malignant mesothelioma therapeutic.
Properties and Applications
Malignant mesothelioma is a tumour that develops in the linings of the lungs, stomach, or heart due to exposure to or inhalation of asbestos. The treatment of mesothelioma can improve the patient’s quality of life and offers enhanced life expectancy. The global malignant mesothelioma therapeutics market can be divided based on segments like product and application.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The industry is divided based on its product as chemotherapy and other therapeutics.
The industry can be broadly categorised based on its application into:
- Hospital Pharmacies
- Retail Pharmacies
- Oncology Centres
- Other
The EMR report looks into the regional malignant mesothelioma therapeutics markets like North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
The growing incidence of malignant mesothelioma among individuals, globally, is driving the industry for malignant mesothelioma therapeutics. One of the main trends in the market is the growing consciousness regarding malignant mesothelioma among individuals owing to efforts of various organisations conducting awareness programmes about cancer and cancer-causing agents such as asbestos, and their effective treatment. A number of screening programs are being conducted for people who are regularly exposed to asbestos, which finds application in building materials, machines, and transport vehicles in the form of hydrated silicates and long thin fibres, to prevent the disease from progressing to advanced stages. Further, the manufacturers and major players in the industry are focusing on the development of novel therapies with fewer side effects and elevated efficacy, which is expected to aid the industry over the forecast period further.
Competitive Landscape
The report presents a detailed analysis of the following key players in the global malignant mesothelioma therapeutics market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Bristol-Myers Squibb Co. (NYSE: BMY)
- Eli Lilly and Co.
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Pfizer Inc.
- Others
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2020 |
| Historical Period | 2016-2020 |
| Forecast Period | 2021-2026 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Application, Product, Region |
| Breakup by Application | Hospital Pharmacies, Retail Pharmacies, Oncology Centers, Others |
| Breakup by Product | Chemotherapy, Other Therapeutics |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Bristol-Myers Squibb Co. (NYSE: BMY), Eli Lilly and Co. (NYSE: LLY), F. Hoffmann-La Roche Ltd. (SWX: ROG), Merck & Co. Inc. (NYSE: MRK), Pfizer Inc. (NYSE: PFE), Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
1.1 Objectives of the Study
1.2 Key findings of the Study
2 Research Methodology
2.1 Data Extraction
2.2 Data Corroboration
2.3 Market Structure
2.4 Inference Data
3 Executive Summary
3.1 Market Overview
3.2 Market Analysis
4 Global Malignant Mesothelioma Therapeutics Market Analysis
4.1 Global Malignant Mesothelioma Therapeutics Market (2016-2020) & Forecast (2021-2026)
4.2 Global Malignant Mesothelioma Therapeutics Market Breakup by Application
4.2.1 Hospital Pharmacies
4.2.2 Retail Pharmacies
4.2.3 Oncology Centers
4.2.4 Others
4.3 Global Malignant Mesothelioma Therapeutics Market Breakup by Application: Historical Market (2016-2020) & Forecast (2021-2026)
4.3.1 Hospital Pharmacies
4.3.2 Retail Pharmacies
4.3.3 Oncology Centers
4.3.4 Others
4.4 Global Malignant Mesothelioma Therapeutics Market Breakup by Product
4.4.1 Chemotherapy
4.4.2 Other Therapeutics
4.5 Global Malignant Mesothelioma Therapeutics Market Breakup by Product: Historical Market (2016-2020) & Forecast (2021-2026)
4.5.1 Chemotherapy
4.5.2 Other Therapeutics
4.6 Global Malignant Mesothelioma Therapeutics Market Breakup by Region
4.6.1 North America
4.6.1.1 United States of America
4.6.1.2 Canada
4.6.2 Europe
4.6.2.1 Germany
4.6.2.2 United Kingdom
4.6.2.3 France
4.6.2.4 Italy
4.6.2.5 Others
4.6.3 Asia Pacific
4.6.3.1 China
4.6.3.2 Japan
4.6.3.3 India
4.6.3.4 ASEAN
4.6.3.5 Others
4.6.4 Latin America
4.6.4.1 Brazil
4.6.4.2 Argentina
4.6.4.3 Mexico
4.6.4.4 Others
4.6.5 Middle East & Africa
4.6.5.1 Saudi Arabia
4.6.5.2 United Arab Emirates
4.6.5.3 Nigeria
4.6.5.4 South Africa
4.6.5.5 Others
4.7 Global Malignant Mesothelioma Therapeutics Market Breakup by Region: Historical Market (2016-2020) & Forecast (2021-2026)
4.7.1 North America
4.7.1.1 United States of America
4.7.1.2 Canada
4.7.2 Europe
4.7.2.1 Germany
4.7.2.2 United Kingdom
4.7.2.3 France
4.7.2.4 Italy
4.7.2.5 Others
4.7.3 Asia Pacific
4.7.3.1 China
4.7.3.2 Japan
4.7.3.3 India
4.7.3.4 ASEAN
4.7.3.5 Others
4.7.4 Latin America
4.7.4.1 Brazil
4.7.4.2 Argentina
4.7.4.3 Mexico
4.7.4.4 Others
4.7.5 Middle East & Africa
4.7.5.1 Saudi Arabia
4.7.5.2 United Arab Emirates
4.7.5.3 Nigeria
4.7.5.4 South Africa
4.7.5.5 Others
5 SWOT Analysis
5.1 Overview
5.2 Strengths
5.3 Weaknesses
5.4 Opportunities
5.5 Threats
6 Porter’s Five Forces Analysis
6.1 Overview
6.2 Buyer’s Power
6.3 Supplier’s Power
6.4 New Entrants
6.5 Degree of Rivalry
6.6 Substitutes
7 Competitive Landscape & Supplier Analysis
7.1 Bristol-Myers Squibb Co. (NYSE: BMY)
7.2 Eli Lilly and Co. (NYSE: LLY)
7.3 F. Hoffmann-La Roche Ltd. (SWX: ROG)
7.4 Merck & Co. Inc. (NYSE: MRK)
7.5 Pfizer Inc. (NYSE: PFE)
7.6 Others
8 Industry Events and Developments
Key Questions Answered in the Report
The global malignant mesothelioma therapeutics market is projected to grow at a CAGR of 7.4% between 2021 and 2026.
The major drivers of the industry, such as the increase in cases of malignant mesothelioma, increasing awareness regarding cancer treatment, growing utilisation of asbestos in various sectors, and growing technological advancements, are expected to aid the market growth.
The growing investment in the development of novel therapies to treat mesothelioma is the key market trend guiding the growth of the industry.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Chemotherapy and other therapeutics are the significant products of malignant mesothelioma therapeutics in the industry.
The major applications of the product include hospital pharmacies, retail pharmacies, and oncology centres, among others.
The major players in the industry are Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., and Pfizer Inc., among others.
Analyst Review
The global malignant mesothelioma therapeutics market is being driven by the rising prevalence of malignant mesothelioma, and the growing awareness regarding its treatment owing to various initiatives taken by the government aided organisations. Aided by the growing research and development of novel therapies, the market is expected to witness a robust growth in the forecast period of 2021-2026, growing at a CAGR of 7.4%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on product, the industry can be bifurcated into chemotherapy and other therapeutics. On the basis of application, the industry is divided into hospital pharmacies, retail pharmacies, and oncology centres, among others. The major regional markets for malignant mesothelioma therapeutics are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., and others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateFive User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?RIGHT PEOPLE
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
RIGHT METHODOLOGY
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
RIGHT PRICE
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
RIGHT SUPPORT
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
The global cancer immunotherapy market stood at a value of around USD 86,607 million in 2020. The market is further expected to grow at a CAGR of 9.7% in the forecast period of 2021-2026 to attain a v...
The global sickle cell disease treatment market stood at a value of around USD 3.4 billion in 2020. The market is further expected to grow at a CAGR of 16.9% in the forecast period of 2021-2026 to att...
The global dry eye disease treatment market attained a value of nearly USD 5 billion in 2020, driven by the rising prevalence of eye complications among the growing geriatric population. Aided by the ...
The global polymyalgia rheumatica treatment market attained a value of nearly USD 177 million in 2020, driven by the introduction of various clinical programs. Aided by the growing demand for physical...
The global haematologic malignancies treatment market attained a value of USD 52.1 billion in 2020, driven by the rising prevalence of hematologic malignancies. Aided by the increasing R&D investment,...
NEWSLETTER